Siguazodan

Research use only, not for human use.

Siguazodan is an effective, selective, orally active phosphodiesterase III ((PDE-III)) inhibitor with an IC50 of 117 nM.

Siguazodan is an effective, selective, orally active phosphodiesterase III ((PDE-III)) inhibitor with an IC50 of 117 nM. Siguazodan inhibited phenylephrine induced 5-HT release with an IC50 value of 4.2 μM。 Siguazodan can increase cAMP accumulation in intact platelets, with EC50 of 18.88 μM.(In Vitro):Siguazodan increases cAMP accumulation in intact platelets with an EC50 of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC50 value of 4.2 μM. In platelet-rich plasma (PRP), Siguazodan inhibits U46619-induced aggregation more potently than that induced by adenosine 5'-diphosphate (ADP), and collagen. Treatment of the PRP with Aspirin has no effect on the potency of Siguazodan. In washed platelets, Siguazodan increases cyclic AMP levels and reduces cytoplasmic free calcium. ADP decreases the ability of Siguazodan to raise cyclic AMP and this may explain its lower potency in inhibiting responses to ADP.(In Vivo):Siguazodan has positive inotropic and vasodilating actions in various laboratory animals and is orally active with a long duration of action in conscious dogs.

SKF 94836

Angiogenesis

PDE

GABA

——

——

115344-47-3

284.3

C14H16N6O

>98% (HPLC)

——

CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C

——

(-20℃)

With Ice Pack

≥ 2 years